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Abstract
The complexity of clinical manifestations commonly observed in autoimmune disorders
poses a major challenge to genetic studies of such diseases. Systemic lupus erythemato-
sus (SLE) affects humans as well as other mammals, and is characterized by the presence
of antinuclear antibodies (ANA) in patients’ sera and multiple disparate clinical features.
Here we present evidence that particular sub-phenotypes of canine SLE-related disease,
based on homogenous (ANAH) and speckled ANA (ANAS) staining pattern, and also ste-
roid-responsive meningitis-arteritis (SRMA) are associated with different but overlapping
sets of genes. In addition to association to certain MHC alleles and haplotypes, we identified
11 genes (WFDC3, HOMER2, VRK1, PTPN3,WHAMM, BANK1, AP3B2, DAPP1, LAM-
TOR3, DDIT4L and PPP3CA) located on five chromosomes that contain multiple risk haplo-
types correlated with gene expression and disease sub-phenotypes in an intricate manner.
Intriguingly, the association of BANK1 with both human and canine SLE appears to lead to
similar changes in gene expression levels in both species. Our results suggest that molecu-
lar definition may help unravel the mechanisms of different clinical features common be-
tween and specific to various autoimmune disease phenotypes in dogs and humans.
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Author Summary
Autoimmune disorders display complex phenotypes with clinically diverse manifestations,
which together with complex genetic inheritance and environmental factors triggering the
disease may complicate the diagnosis and investigation of the disease mechanism. The use
of dog breeds may facilitate the analysis of genetic factors based on genetic homogeneity
within a breed. We performed genetic analysis of two diseases common in dogs, immune-
mediated rheumatic disease (IMRD) and steroid-responsive meningitis-arteritis (SRMA)
that are similar to human SLE and a group of vasulitides such as Kawasaki disease,
Henoch-Schönlein purpura and Behçet’s disease, correspondingly. We identified eleven
genes along with specific alleles and genotypes for the major histocompatibility complex II
involved in susceptibility, and studied their expression. The genes shared between the two
diseases may be involved in the common immune signaling pathways and hence account
for the common clinical signs, whereas the phenotype-specific genes may be implicated in
particular pathways active in certain tissues and organs, and thereby may be responsible
for characteristic manifestations seen only in one of the diseases. Further, the similarity be-
tween human and dog SLE at the genetic and functional levels demonstrated by the associ-
ation of the BANK1 gene in both species indicates the common cross-species mechanisms
of autoimmunity and may help identification of novel disease genes and pathways.
Introduction
SLE is a chronic autoimmune disorder caused by multiple genetic and environmental risk fac-
tors. The disease tends to be clinically heterogeneous [1], with manifestations ranging from rel-
atively mild symptoms such as skin rash to severe impairment of functions of kidney, heart,
lung, central nervous system and other organs [2, 3]. A hallmark of the disease is the produc-
tion of autoantibodies directed to self-antigens located in the nucleus, cytoplasm or on the cell
surface. Antinuclear antibodies (ANA) are found in more than 95% of human SLE cases [4].
While SLE and SLE-related diseases were first described in human patients, they are also
seen in other species including dogs with similar clinical manifestations [5–8], which makes
dog a good comparative model for genetic studies of human SLE. Nova Scotia duck tolling re-
triever (NSDTR) dogs appear to be predisposed to an SLE-like disease called immune-mediat-
ed rheumatic disease (IMRD) [5], and also show strong predisposition to another related
immune-mediated disease, steroid-responsive meningitis-arteritis (SRMA), which share some
features with human vasculitides including Kawasaki disease [9–14], Henoch-Schönlein pur-
pura [15] and Behçet’s disease [16].
It was shown in the recent years that circulating autoantibodies could be linked to specific
types of both canine and human autoimmune diseases [8, 17–19]. The immunofluorescent
ANA test reveals two major patterns of ANA, homogeneous with a concomitant cytoplasmic
and chromosomal reactivity and speckled with only cytoplasmic antigens stained. A previous
study showed that among canine IMRD cases positive for indirect immunofluorescence (IIF)-
ANA, 61% showed the speckled pattern (ANAS), whereas 39% displayed homogeneous pheno-
type (ANAH) [5]. While the link between autoantibodies and sub-phenotypes of disease may
be evident, especially in the case of tissue-specific antigens, the genetic factors behind this con-
nection are not well known.
To date, autoimmune diseases in both humans and dogs have been found associated with
both major histocompatibility complex (MHC) class II alleles [20–25] and many other suscep-
tibility genes [26, 27]. Out of 40 loci that have been associated with human SLE the causative
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variant and susceptibility mechanism has been described only for a few [28], leaving a lot of re-
maining work in understanding genome function and genotype-phenotype correlations.
Overall, dogs share many of man’s common diseases, but they also have a unique genome
structure, which greatly facilitates genome wide association studies (GWAS) and, compared to
human studies, significantly fewer genetic markers and samples are required for gene mapping
in dogs [29, 30]. This is a result of the canine genome architecture characterized by high linkage
disequilibrium within breeds being 40- to 100-fold longer compared to that observed in the
human genome. The genomic architecture of domestic dogs has been formed by multiple ge-
netic bottlenecks, founder effects and restricted breeding practices [30]. Gene mapping in dogs
has proven successful with only ~100 cases and ~100 controls for complex traits and the list of
disease-causing genes that have been identified in dogs is constantly growing (some are re-
viewed in [31, 32]).
In fact, in the first successful GWAS for a canine complex trait we mapped five loci for
IMRD and SRMA using only 57 controls and 81 cases including 37 with IMRD and 44 with
SRMA [27]. To replicate these loci we performed fine-mapping using a total of 160 cases in-
cluding 82 dogs with IMRD and 78 with SRMA and 173 controls, and replicated all of the five
loci in at least one of the phenotypes analysed [27].
In this study, we have performed further functional and genetic dissection of all five GWAS
loci identified previously. We present evidence for the association of 11 genes located on five
chromosomes and specific genotypes for the canine leukocyte antigen (DLA, equivalent to
MHC) class II to different sub-phenotypes of SLE-related disease and SRMA in dogs, as well as
study the correlation between the associated SNPs and haplotypes and an altered expression of
genes in the respective loci.
Results
Association of the speckled ANA pattern with DLA class II risk haplotype
and general homozygosity for DLA haplotypes with the homogeneous
ANA phenotype
We first performed an indirect immunofluorescent ANA test on serum from 59 cases and 63
healthy control NSDTRs. Of these, 26 cases were classified as ANAH and 27 cases as ANAS (six
cases could not be classified due to lack of serum) (Fig 1), while all healthy controls were
ANA-negative. The polymorphic exon 2 was sequenced for each of the DLA-DRB1,-DQA1
and-DQB1 genes in all dogs (S1 Table). A total of five DLA-DRB1, four DLA-DQA1 and five
DLA-DQB1 alleles, forming five different haplotypes were identified (S2 and S3 Tables). Ten
different genotypes were observed in the study population (Table 1). Association analysis was
performed for alleles, haplotypes and genotypes for the ANAH and ANAS case groups separate-
ly as well as the combined case group, and each was compared to controls (Table 1, S2 and S3
Tables).
There was a significant association with haplotype 2 in ANAS cases compared to the control
group (OR = 9.7 and p =<0.0001) (S3 Table), and an even higher OR in homozygote individu-
als (OR = 21.0 and p<0.0001; genotype 2; 77.8% in ANAS cases vs. 14.3% in controls)
(Table 1). In total, 93% of the twenty-seven ANAS dogs were either homo- or heterozygous for
haplotype 2 (DLA-DRBI00601/DQA1005011/DQB102001) and twenty-one of them
(77.8%) were homozygous.
No significant association was observed between the haplotypes or genotypes of DLA and
the cases with ANAH pattern. However, at the allelic level a significant association was identi-
fied for the DQA100601 (86.5% in ANAH cases compared to 55.6% in controls; OR = 5.1 and
p = 0.00017, S2 Table).
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As homozygosity has been hypothesized to be a risk factor in itself, we removed the ANAS
risk genotype and analyzed the remaining data for association to homozygosity regardless of
haplotype. We found an increase in homozygosity in ANAH cases (62.5%) vs. controls (14.8%),
implicating a general homozygous disadvantage at DLA class II for ANAH dogs (OR = 9.6,
p<0.0001; S4 Table).
Fig 1. Indirect immunofluorescence staining of HEp-2 cells treated with serum from patient dogs. ANAs directed against specific nuclear antigens
reveal different patterns on stained cells.A) Speckled ANA pattern. Arrows point at mitotic cells with negatively stained chromosomes surrounded by positive
nucleosome staining.B) Homogeneous ANA pattern. The positive staining of chromatin in dividing cells is shown by arrows.
doi:10.1371/journal.pgen.1005248.g001
Table 1. Genotype frequencies in the NSDTR population indicate an increased frequency for ANAS dogs homozygous for haplotype 2
(DLA-DRB1*00601/DQA1*005011/DQB1*02001) compared to controls and an increase in frequency for ANAH dogs with a homozygous haplotype
















1 1.1 20.3 38.5 0.0 9.5 14.8 5.9 NA
2 2.2 40.7 7.7 77.8 14.3 27.0 21.0 <0.0001
3 3.3 10.2 19.2 3.7 3.2 6.6 7.3 NA
4 1.2 8.5 3.8 11.1 28.6 18.9 - -
5 1.3 11.9 23.1 0.0 17.5 14.8 - -
6 1.5 5.1 3.8 3.7 4.8 4.9 - -
7 2.3 1.7 3.8 0.0 12.7 7.4 - -
8 2.5 1.7 0.0 3.7 4.8 3.3 - -
9 3.5 0.0 0.0 0.0 3.2 1.6 - -
10 1.4 0.0 0.0 0.0 1.6 0.8 - -
S = Speckled, H = Homogeneous
Bold indicate between what groups the largest allele frequency difference occurred and where statistics were performed (OR and P-values).
doi:10.1371/journal.pgen.1005248.t001
Multiple Changes of Genes Predispose to SLE
PLOSGenetics | DOI:10.1371/journal.pgen.1005248 June 9, 2015 4 / 27
Distinct risk loci additionally contribute to susceptibility to IMRD and
SRMA
To search for candidate variants, the five genetic risk loci on CFA 3, 8, 11, 24 and 32 that were
previously identified by GWAS to be associated to IMRD and SRMA [27] were re-sequenced
in four ANA-positive cases, two SRMA cases and three healthy dogs using Nimblegen capture
and Illumina sequencing. Using standard methods, a total of 13,084 SNPs and 2,780 indels
were detected. No structural changes or CNVs that differed between cases and controls were
identified. Among those, 426 SNPs and 88 indels showed a potential functional effect by SeqS-
coring [33]. Next, 308 SNPs following the risk haplotype patterns were chosen for genotyping
in the entire sample set (S5 Table). For each locus, association analysis was performed between
the 132 healthy controls and each of the different sub-phenotypes: 1) SRMA-affected dogs
(N = 66), 2) all ANA-affected dogs (N = 52), 3) ANAS (N = 24) and 4) ANAH staining pattern
(N = 21). Furthermore, two conditional analyses were performed where only ANAS dogs ho-
mozygous for DLA risk haplotype 2 (N = 18) and ANAH dogs homozygous for DLA (N = 14)
and ANAH dogs with the DQA100601 allele (N = 16) were included respectively. For the risk
locus on chromosome 11 the strongest association was observed with all ANA dogs (Fig 2), for
the risk locus on chromosome 24 the strongest associated sub-phenotype was the ANAH dogs
homozygous for DLA (Fig 3), while the risk locus on chromosome 32 showed two independent
association signals for SRMA and ANAS with and without DLA association (Fig 4); and the
risk locus on chromosome 3 showed signals for all ANA, and for ANAH and ANAS tagged by
different haplotypes, and to a lesser extent to SRMA (Figs 5 and 6). Finally, the risk locus on
chromosome 8 also showed two separate signals to SRMA and ANAH dogs associated DLA
(Fig 7). Of note, in the current report, as we further investigate the already associated and repli-
cated regions [27], we used raw p-values focusing on the highest peaks for each sub-phenotype
to investigate its effect on gene expression. These regions have already been replicated in our
previous genome-wide association study with P values ranging between 10-5-10-6, with three
loci on chromosomes 3, 11 and 24 reaching genome-wide significance following fine-mapping
and validation with P values of 10-11-10-13 [27]. The results are discussed in more detail below,
together with expression analysis of the genes at each locus.
Down-regulation of PTPN3 is associated with risk for ANA-positive IMRD. On chro-
mosome 11, the strongest association was seen between all ANA cases and a SNP (CanFam2.0
chr11:67,537,177, p = 2.310–4) located within the non-receptor type 3 protein tyrosine phos-
phatase gene (PTPN3) (Fig 2A). The top SNP was in almost complete LD with 14 other SNPs
(r2>0.9 for all pairs) (Fig 2B) forming a 58 kb haplotype overlapping the 3’ end of the gene.
The risk haplotype had an allele frequency of 19.4% in cases versus 7.2% in controls (Fig 2C).
Based on the strong LD, three SNPs from the haplotype were selected (one in the 3’UTR, a
SNP in intron 18 and one synonymous SNP in exon 18: 11:67,516,041, 11:67,538,032 and
11:67,538,806, respectively) and then the genotypes were correlated with PTPN3mRNA levels
measured in total RNA purified from peripheral blood mononuclear cells (PBMC) of 167
healthy NSDTRs (Fig 2D). The expression of PTPN3 was substantially down regulated in het-
erozygotes (7-fold change, PANOVA<0.0001). As only one dog was found to be homozygous for
the risk haplotype among the 167 healthy dogs, it was not included in the statistical analysis,
but we noted that this dog showed extremely low levels of PTPN3 expression. To examine
whether all three genotypes could be represented in the expression analysis, a synonymous
SNP in exon 3 (11:67,583,604, p = 0.43) falling just outside the most associated haplotype
(r2 = 0.23) was selected for analysis in combination with the other three SNPs from the risk
haplotype. This SNP contributed to the down-regulation both independently and in combina-
tion with the risk haplotype (Fig 2D), suggesting a cumulative effect on gene expression levels
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Fig 2. Genetic analysis of chromosome 11 locus and PTPN3 expression. (A) The strongest association signal was observed for the ANA-positive IMRD
phenotype and overlaps with the PTPN3 gene. The red circles show the SNPs that correlate with gene expression and indicated for all associated sub-
phenotypes. The gene structure is shown below with exons as vertical bars, the direction of transcription is indicated by red arrowhead. (B) A 15 SNP risk
haplotype identified for ANA-positive cases, all SNPs in almost complete LD (r2 >0.9 for all pairs) with the top associated variant (11:67537177). (C)
Haplotype frequencies in cases and controls. The SNPs used for expression studies are shown in bold and their risk alleles in red. (D) The log-transformed
mRNA levels of PTPN3 in the PBMCs of dogs with different haplotypes comprised of SNPs in the 3’-UTR and intron 18 and two synonymous SNPs in exons
18 and 3. The protective haplotype is T/T-C/C-A/A-C/C is shown in blue color, the associated risk haplotypes T/C-C/A-A/G-T/T and C/C-A/A-G/G-T/T—in red
color. The PTPN3 gene is down-regulated 7-fold in the heterozygous risk haplotype compared to the protective haplotype. Boxes represent interquartile
range 25–75%with median, and 5–95 percentile range with maximum and minimum values. The dog number in each group is shown next to the haplotypes.
The gene expression was normalized to the levels of the reference gene TBP and analyzed using a one-way ANOVA. All phenotypes and SNP labels as well
as gene structures, expression and normalization presented here are unified with the figures for other loci.
doi:10.1371/journal.pgen.1005248.g002
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from the risk haplotype and the exon 3 variant. Among the cases used in the association study,
only four dogs were homozygous for the risk haplotype C/C-A/A-G/G-T/T (11:67,516,041,
11:67,538,032, 11:67,538,806 and 11:67,583,604, respectively) and three of them showed severe
IMRD that eventually led to death (one dog died at the age of 19 months, and two at 6 years of
age).
Up-regulation ofWFDC3 correlates with risk for ANAH in combination with homozy-
gosity for DLA. The strongest association for the risk locus on chromosome 24 was identified
for a sub-phenotype of ANAH in combination with a homozygous DLA haplotype (Fig 3A).
Seven SNPs in high LD (r2>0.9) (Fig 3B) define a risk haplotype that overlaps two genes cod-
ing for WAP four-disulfide core domain protein 3 (WFDC3) and terminal deoxynucleotidyl-
transferase interacting protein 1 (DNTTIP1) and is present at a frequency of 69.2% in cases
and 38.6% in controls (Fig 3C). The mRNA expression in PBMCs of these two genes was ana-
lyzed in detail. Several other genes located upstream in the locusWFDC13,WFDC10B, SPINT4
and SPINT5 were found not to be expressed in either PBMCs or 13 diverse dog tissues ana-
lyzed. The top SNP, located in intron 3 of DNTTIP1 (24:36,087,012, p = 4.510–4), is associated
with expression ofWFDC3 (1.4-fold change, PANOVA = 0.0075) (S6 Table), whereas neither al-
ternative splicing nor expression changes for the DNTTIP1 gene were detected. Both genes are
separated by less than 3 kb and placed head-to-head, whereby intronic SNPs in DNTTIP1
could serve as distal upstream enhancers forWFDC3. The two synonymous variants in exon 3
and exon 5 ofWFDC3 are also strongly associated with gene expression (24:36,075,761,
1.4-fold, PANOVA = 0.0039, r
2>0.9 with 24:36,087,012; 24:36,066,098, 1.4-fold, PANOVA =
0.0076, r2>0.9) (S6 Table). Since all three variants are in high LD, and the two synonymous
SNPs have stronger or equal association with transcription compared with the top SLE SNP
24:36,087,012, we decided to determine the combined effect of the three-SNP haplotype
(24:36,066,098, 24:36,075,761, 24:36,087,012) on gene expression. TheWFDC3 gene is upregu-
lated 1.4-times in the risk haplotype G/G-A/A-C/C (PANOVA = 0.005) compared to protective
A/A-C/C-G/G (Fig 3D).
Two independent association signals on chromosome 32 link to ANA and SRMA respec-
tively. Association for the risk locus on chromosome 32 was observed in multiple sub-pheno-
types. In ANAS dogs that were homozygous for DLA haplotype 2 and to a lesser extent in “all
ANA” and homogeneous ANA with DLA DQA100601 allele and general homozygosity for
DLA (Fig 4A), the signal was located between theMTTP and DAPP1 genes and included eight
SNPs in complete LD (r2 = 1) on a 41 kb haplotype (32:24,514,629–24,565,468, best associa-
tion: p = 4.010–4) (Fig 4B). In contrast to ANA phenotypes, the association with SRMA did
not form a single risk-haplotype, but instead was spread over a 1.3 Mb region (32:24,827,518–
32:26,115,349) (Fig 4A). While no strong LD was identified, 11 SNPs out of 131 genotyped for
this chromosomal region have an r2 between 0.6–0.8 across the whole region (Fig 4C).
To examine the functional effect of the risk genotypes, we measured mRNA expression of
all nine genes from the locus in the PBMCs of healthy dogs (Fig 4E–4I, S1 Fig). We genotyped
24 highly associated SNPs across the entire region and correlated them with expression of the
genes (S7 Table). Interestingly, the ANAS/ANA/ANAH associated haplotype that occurs more
frequently in patients (23.5%) than healthy controls (8.8%) (Fig 4D) was only significantly cor-
related with a 1.5-fold up-regulation of the BANK1 gene (PANOVA = 0.0007), located 1.5 Mb
Fig 3. Genetic and gene expression analyses for chromosome 24 locus. (A) The strongest association was observed for the ANAH dogs with a
homozygous DLA haplotype (14 patient dogs) in the region that containsWFDC3 and DNTTIP1 genes. Differentially expressed geneWFDC3 is labeled with
bold font. (B) r2 analysis was performed on the top SNP (24:36087012) and revealed a seven SNP risk haplotype (r2>0.9) overlapping theWFDC3 and
DNTTIP1 genes. (C) Haplotype frequencies in cases and controls. (D) The increased transcript level ofWFDC3 in the risk haplotype made of two
synonymous SNPs (24:36066098, 24:36075761) and the top SLE variant.
doi:10.1371/journal.pgen.1005248.g003
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downstream from the top SNP 32:24,542,001, which suggests a long-range regulatory effect
(Fig 4E).
The top SNP (chr32:24,827,518) for SRMA, on the other hand, was also the SNP associated
with the most significant expression changes for the following genes: DAPP1, LAMTOR3,
DDIT4L and PPP3CA. The risk allele A correlated with enhanced gene expression levels
(1.7-fold for DAPP1, PANOVA = 0.001; 1.9-fold for LAMTOR3, PANOVA = 0.008; 2.5-fold for
DDIT4L, PANOVA<0.0001; 2-fold for PPP3CA, PANOVA = 0.01) (Fig 4F–4I).
Complex changes of gene functions in the chromosome 3 locus are associated with both
ANA-positivity and SRMA. Association of the risk locus on chromosome 3 was identified
for ‘all ANA’ dogs including speckled and homogeneous sub-phenotypes (Fig 5A) with the top
SNP (chr3:57,432,981, p = 4.910–4) linked to a four SNP haplotype in strong LD (r2>0.9) (Fig
5B), where the haplotype overlaps the AP3B2 gene and extends towards the FSD2 gene. A sec-
ond haplotype consisting of 18 SNPs in strong LD (r2>0.9) with a SNP at chr3:57,484,486 (Fig
5C) was located upstream of theWHAMM gene and associated to the ‘all ANA’ (p = 5.610–3)
and the speckled phenotypes (p = 2.210–2). Interestingly, this complex haplotype was associat-
ed with SRMA (p = 2.610–2) (Fig 5A). Separately, we also identified an association for the phe-
notype of ANAH + DLA-DQA100601 to a SNP located in theHOMER2 gene
(chr3:57,546,568, p = 1.210–3, Fig 5A). No LD was observed between this SNP and the other
strongly associated SNPs (Fig 5D).
Next, the mRNA expression of the four genes located within the borders of the associated
region was analyzed. We found that three genes, AP3B2,WHAMM and HOMER2, are ubiqui-
tously expressed while FSD2 expression is restricted to skeletal muscle, heart, kidney, testis,
skin, and very low levels detected in cartilage (S2 Fig). Due to low minor allele frequencies, we
could not collect enough tissue samples from genetically different NSDTRs to analyze FSD2 ex-
pression, and thus we could not rule out entirely the possibility for this gene to be affected by
the associated variants in a particular tissue.
However, the most associated SNP for ‘all ANA’ (located between AP3B and FSD2) was
most associated with expression ofWHAMM. The minor risk allele T correlates with up-regu-
lation ofWHAMMmRNA expression (1.4-fold, PANOVA<0.0001), while showing almost no bi-
ologically significant effect on AP3B2 (1.07-fold median change, P = 0.036) (S8 Table). On the
contrary, the associated SNP 3:57,484,486 located upstream ofWHAMM, exerted a more pro-
found effect on AP3B2 transcription (1.5-fold, PANOVA = 0.004), thus indicating the existence
of negative cross-regulation of the two genes.
The expression ofHOMER2 was not associated with any of the SLE-related variants, al-
though differential regulation of the gene marginally associated with some genetic variants
was found (S3A Fig), suggesting that there may be an independent eQTL variant(s) not direct-
ly related to the sub-phenotypes studied here. When a 2 SNPs haplotype (3:57,432,981–
3:57,546,568) was considered by combining the associated SNPs at the two ends of this locus
(near AP3B2 and within HOMER2), the effect onWHAMM increased compared to when ei-
ther of the two SNPs were examined separately (1.5-fold, PANOVA<0.0001, Fig 6A, S3B Fig).
Interestingly, the top SNP 3:57,432,981 is a common variant tagging two risk sub-haplo-
types: (3:57,432,981–3:57,484,486) and (3:57,432,981–3:57,546,568) occurring in 26% and 16%
Fig 4. Genetic and gene expression analyses for chromosome 32 locus. (A) Strong association to the locus was observed in ANA and independently in
SRMA-affected dogs. The signal for ANA dogs is located between theMTTP and DAPP1 gene. SRMA dogs showmultiple strong signals spread over a
1.3 Mb region. (B) ANAS dogs homozygous for DLA haplotype 2 show a narrow eight SNP risk haplotype with complete LD (r2 = 1) with the top SNP
(32:24542001). (C) No strong LD was identified for the top SNP (32:24827518) in SRMA dogs, but r2 of 0.6–0.8 occurs throughout the region. (D) Haplotype
frequencies in cases and controls in ANAS dogs. (E-I)Genes with differential expression in the blood cells associated with two top variants (32:24542001 for
ANAS-DLA 2.2) with BANK1 (E), and (32:24827518 for SRMA) with DAPP1 (F), LAMTOR3 (G), DDIT4L (H), PPP3CA (I).
doi:10.1371/journal.pgen.1005248.g004
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of patients, correspondingly (Fig 6B). While the first haplotype is associated more with general
ANA positivity, the second one is associated with homogeneous ANA staining and even more
specifically with a particular DLA risk allele. This could suggest that depending on the second
SNP in the risk haplotype, the combination of affected genes (AP3B2 and to a lesser extent
WHAMM (Fig 6C, S4 Fig), orWHAMM and HOMER2 (Fig 6A and 6D)) may determine
what pathways are under impact and hence, what disease phenotype could be expected.
In contrast to all the regulatory variants seen here, the associated SNP located within
HOMER2 (chr3:57,546,568) (Fig 5A and 5D), is a non-synonymous variant in exon 3 of the
HOMER2 gene causing a Thr to Ala substitution. The substitution is located in the β5 strand of
a highly conserved EVH1 protein domain and is close to the key amino acids participating in
the formation of the HOMER2 ligand-binding site (Fig 6D, S5 Fig) [34, 35]. Analysis with
Fig 5. Genetic analysis of chromosome 3 locus. (A) The strongest association signals were observed in all ANA-positive dogs in the AP3B2 and in the
intergenic region between AP3B2 and FSD2 genes, followed by a single SNP peak in the HOMER2 gene (3:57546568) associated ANAH dogs with the risk
allele DLA-DQA1*00601. (B) The top SNP for ANA-positive dogs (3:57432981) occurs in a four SNP haplotype with strong LD (r2>0.9). (C) Another
associated region was identified for ANA-positive dogs (top SNP 3:57484486) in an 18 SNP haplotype with strong LD (r2>0.9). (D) ANAH dogs with the risk
DLA-DQA1*00601 show one top SNP (3:57546568) independent of other variants.
doi:10.1371/journal.pgen.1005248.g005
Fig 6. Chromosome 3 risk haplotypes and their effects on genes. (A) The haplotype made of SNPs 3:57432981–3:57546568 is best associated with
expression changes ofWHAMM (1.5-fold up-regulation in the risk, P<0.0001), while AP3B2was not altered in this haplotype. (B) The frequencies of the
haplotypes made of the top SNPs that represent three independently associated regions. (C) The second risk haplotype (3:57432981–3:57484486) is
stronger associated with up-regulation of AP3B2 (1.5-fold, P = 0.007) and to a lesser extent withWHAMM (1.2-fold up-regulation, P = 0.016, S4 Fig). (D) The
schematic structure of the HOMER2 protein with the EVH1 domain and a coiled coil region. The amino acid sequence is shown below for the region from β4
to β6 strands. The nonsynonymous variant 3:57546568 changes Thr (blue color, protective) to Ala (red color, risk) in the HOMER2 protein. An asterisk marks
the hydrophobic core residue and the two amino acids critical for the peptide binding site are marked with diamonds.
doi:10.1371/journal.pgen.1005248.g006
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SIFT [36] and PROVEAN [37] suggests that the variation is rather deleterious for
protein function.
Chromosome 8 SNPs in gene desert associated with ANAH and SRMA phenotypes.
The association signals on chromosome 8 fall into a 2 Mb gene-desert, downstream of the
VRK1 gene. The strongest association was observed in SRMA dogs (chr8:68,726,546,
p = 2.210–3), but also the phenotype: ANAH + risk allele DLA-DQA100601 showed signifi-
cant association to two SNPs (chr8:68,712,185, p = 6.710–3 and chr8:68,708,503, p = 8.710–3)
(Fig 7A). All three variants are not in LD with each other (Fig 7B and 7C, S6 Fig). The only
close gene, VRK1, is located over 100 kb upstream of the signals, and its expression measured
in the blood cells was found associated with the two ANAH risk variants when analyzed using
the two available genotypes only: major protective and heterozygous (Fig 7D). Due to low
minor allele frequencies, only one dog homozygous for the ANAH risk variants was found in
the study cohort, thus limiting the power of statistical analysis of the VRK1 expression.
Among the three top variants, only SNP chr8:68,708,503 lies in a region with high regulato-
ry potential as predicted by ESPERR [38] (Fig 7C). This region also contains enhancer-associ-
ated H3K4Me1 histone-modification marks in lymphablastoid cells, ENCODE ChIP-seq and
DNAse I hypersensitive sites. The SNP is located only 5 bp from a highly conserved Pou5f1/
Oct4 binding site [39]. In addition, the risk allele A creates a binding site for signal transducer
and activator of transcription (STAT) family transcription factors. Interestingly, Oct-1 and
STAT5, members of the Pou domain-containing and STAT family transcription factors, corre-
spondingly, were shown to form stable transcription complexes upon cell activation with cyto-
kines and induce cyclin D1 expression [40]. In order to verify the regulatory effect of this
variant, we cloned the 550 bp DNA fragment in the pGL4.26 vector, and after transfection into
K562 cells performed the luciferase assay. We confirmed that the risk allele A indeed enhances
expression in both non-stimulated and stimulated cells (Fig 7E). We conclude that the SNP
chr8:68,708,503 not only has a proven regulatory potential but might be involved as a part of
an enhancer in the upregulation of the VRK1 gene in the risk for ANAH.
Discussion
SLE and other autoimmune diseases occurring in humans have been intensely studied over the
past years due to high heritability of such diseases and the availability of modern genetic tools.
The most recent review article reports over 40 loci associated with human SLE [28]. The het-
erogeneity of SLE reflected by the 11 diagnostic criteria established by the American College of
Rheumatology (ACR) [2, 3] supports the current understanding that the genetic factors under-
lying such disparate clinical manifestations could be different as well. Recently, differential ge-
netic associations with SLE based on the anti-dsDNA autoantibody status, either anti-dsDNA
positive or anti-dsDNA-negative SLE, were reported [41]. The study of the relationships be-
tween the SLE risk alleles and clinical sub-phenotypes led to the finding that certain lupus
manifestations are more dependent on the presence of multiple risk alleles, while others are
Fig 7. Genetic and gene expression analyses for chromosome 8 locus. (A) Two independent strong association signals were observed for SRMA
affected dogs (8:68726546) and ANAH dogs with DLA risk allele DLA-DQA1*00601(8:68712185 and 8:68708503). The only closest gene, VRK1, is located
over 100 kb upstream of the associated region while there are no protein-coding genes for more than 1.9 Mb downstream. The black circle indicates the
SRMA SNP not associated with expression changes of VRK1, the red circles—SNPs associated with VRK1 expression. (B) No SNPs were in LD with the top
SRMA SNP. (C) The SNP 8:68708503 for ANAH dogs with DLA risk allele DLA-DQA1*00601 is not in LD with any other genotyped variants, but have a
strong regulatory potential. The 1 kb region aligned with the corresponding human fragment is shown below with several tracks for gene regulation and
conservation displayed. (D) Expression levels of the VRK1 gene in the blood cells of healthy NSDTRs stratified by SNP 8:68708503. Only one dog
homozygous for the risk A allele was available. (E) The DNA fragment with the SNP 8:68708503 was cloned in the luciferase reporter vector and following
transfection in K562 cells the protein lysate was assayed for enzyme activity. The risk allele A enhances luciferase expression comparing to the protective C
allele in both unstimulated and stimulated with PMA cells.
doi:10.1371/journal.pgen.1005248.g007
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more strongly associated with a single variant, for example, renal disease more significantly as-
sociated with HLA-DRB1, and arthritis with the protective allele of ITGAM [42]. Interestingly,
a third group of sub-phenotypes (malar rash, discoid rash, photosensitivity, serositis, and neu-
rological disorders) was found not to be associated with the currently known SLE susceptibility
genes, suggesting either the presence of not yet identified factors or potentially non-genetic fac-
tors, such as environmental conditions or epigenetic effects.
Dogs, like other mammalian species also develop autoimmune disorders. Furthermore, the
existence of canine breeds such as NSDTRs, which are predisposed to the development of auto-
immune diseases, make them potentially useful for mapping disease genes and finding novel
disease pathways [31]. A hallmark of SLE-related immune-mediated rheumatic disease
(IMRD) in dogs is the presence of ANA autoantibodies, which display two major patterns
when stained with indirect immunofluorescence, homogeneous and speckled ANA. Both sub-
phenotypes have overlapping clinical and pathological features in NSDTRs such as musculo-
skeletal signs, including stiffness and joint pain without joint swelling, sometimes muscle pain
and lymphopenia; and all dogs showed good response to corticosteroid treatment [5]. The pos-
sible link between different ANA patterns and various clinical signs for SLE was previously ob-
served for a group of dogs including German Shepherds, NSDTRs, and several other breeds
[8]. Of note, in our NSDTR sample set, skin lesions were present in the ANAH group, while
muscle pain and fever were slightly more frequent in the ANAS group (S9 Table). The onset of
disease in the study cohort was at a median age of 3 years for ANAH dogs and less than 2 years
for ANAS dogs.
The MHC region has the strongest association to many autoimmune diseases in humans
due to its utmost importance in the recognition of antigens; and it was also shown to be impor-
tant for canine SLE [25]. Moreover, certain genotypes such as the HLA-DRB103:01 was found
recently to be significantly associated with specific sub-phenotypes with anti-Ro/SSA and anti-
La/SSB autoantibodies [43]. In dogs, we observed that different DLA genotypes and alleles
were associated with either ANAH or ANAS, which may indicate the reactivity towards certain
autoantigens produced more frequently in a particular ANA pattern.
Among the seven genes associated with “all ANA”,WFDC3,HOMER2 and VRK1 are clearly
not associated with ANAS reactivity (Table 2). Moreover, for these genes the cumulative
Table 2. Genes associated with IMRD and SRMA phenotypes.
chromosome SNP ID gene/phenotype gene effect all ANA ANAS ANAS+DLA ANAH ANAH+DLA SRMA
11 11:67537177 PTPN3 down + + + + + -
24 24:36087012 WFDC3 up + - - + + -
32 32:24542001 BANK1 up + + + - + -
32:24827518 DAPP1 up - - - - - +
32:24827518 LAMTOR3 up - - - - - +
32:24827518 DDIT4L up - - - - - +
32:24827518 PPP3CA up - - - - - +
3 3:57484486 AP3B2 up + + - - - +
3:57432981 WHAMM up + + - + + -
3:57546568 HOMER2 nsSNP (Thr->Ala)1 + - - + + -
8 8:68708503 VRK12 up + - - + + -
The strongest genetic association to a phenotype marked with bold “+”, regular “+” means the gene is associated with a particular phenotype. 1-we
observed also a trend towards down-regulation of HOMER2 in the risk haplotype, although it did not reach statistical signiﬁcance due to small sample size.
2-the strong genetic association signal with SRMA on chromosome 8 was not associated with VRK1 expression levels
doi:10.1371/journal.pgen.1005248.t002
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association with DLA, either general homozygosity for any DLA haplotype or the
DQA100601 allele, plays a somewhat stronger role. The AP3B2 gene is associated with “all
ANA”; and also has equally strong signals for two phenotypes, the speckled ANA group and
SRMA, but no association with ANAH. Interestingly, the observed genetic segregation may
favor a previously suggested hypothesis based on the differences in clinical manifestations that
ANAS pattern could represent another SLE-related disorder, while the ANAH is more similar
to human SLE [5]. The PTPN3,WHAMM and BANK1 genes are associated with both ANA
sub-phenotypes and thus could be considered as common genes.
A function ofWHAMM (WAS protein homolog associated with actin, Golgi membranes
and microtubules), a gene previously reported to participate in Golgi transport and membrane
remodeling, and cytoskeleton formation by binding to microtubules and promoting actin poly-
merization [44], has not been described before in immunity, while the other two common
genes PTPN3 and BANK1 implicate major perturbations in both T and B cells. Human protein
tyrosine phosphatase PTPH1 encoded by the PTPN3 gene inhibits T cell-activation by dephos-
phorylating the immune tyrosine-based activation motifs (ITAM) in the TCRz chain that re-
sults in a downstream inhibition of NF-AT [45, 46]. The observed substantial reduction of the
PTPN3mRNA levels in dogs carrying the risk haplotypes may cause a sustained activation of
TCR signaling and lead to development of autoimmune disease. The BANK1 gene encoding
the B-cell scaffold protein with ankyrin repeats was previously found associated with human
SLE and other autoimmune diseases in distinct populations and ethnic groups [47–53]. The ex-
pression of the human BANK1 gene, similarly to what we found in IMRD dogs, is up-regulated
in patients carrying the risk alleles [54]. This may suggest a common disease mechanism in the
human and dog diseases.
Whether or not and to what extent, the individual genes contribute to a particular ANA-
staining pattern, and more generally, to specific clinical manifestations, and what interplay
could be between the associated genes and their pathways, remains to be further studied. Also,
while the identity of major autoantibodies present in the serum of human individuals with dif-
ferent ANA reactivity is already known [18], it needs to be studied in more detail in dogs.
SRMA, on the other hand, differs from IMRD by displaying predominantly neurological
signs including pain, cervical rigidity, pyrexia and a polymorphonuclear pleocytosis of the cere-
brospinal fluid (CSF) [10]. The disease usually occurs at a young age (4–19 months) and is
characterized by inflammation of leptomeninges and vasculitis of the leptomeningeal and me-
diastinal blood vessels, including arteritis of heart, thymus, and also vessels of the thyroid
glands and muscles [55, 56]. The disease can be treated with immunosuppressive doses of corti-
costeroids similarly to IMRD [14]. While the etiology is largely unknown, it has been proven
that inflammatory processes in the CNS are not caused by viral or bacterial infection [14].
The strongest genetic association with SRMA detected in NSDTRs is located on chromo-
some 32, followed by signals on chromosome 8 and 3. Although there is no strong LD (r2<0.8)
between the genetically associated variants on chromosome 32, the presence of multiple highly
associated SNPs across the 1.3 Mb region and their association with gene expression levels sug-
gests that the entire region including several genes is important for SRMA susceptibility. While
many typed variants show correlation with gene expression, there is one tag SNP
(chr32:24,827,518) whose risk allele A is most strongly associated with increased expression of
DAPP1, LAMTOR3, DDIT4L and PPP3CA. The distant cis-effect on expression of genes placed
far away from each other may indicate a complex topology of the chromosomal locus with a
possible locus control region(s) and common enhancers driving regulation of genes located on
the opposite DNA strands.
The previously reported signal on chromosome 8 [27] was corroborated in our study, but
we found no correlation between the SRMA SNPs and expression levels of the only nearby
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gene VRK1. Thereby, the identity of the gene affected in this locus in SRMA remains to be
identified or the SNP could have its effect in a different tissue than PBMCs. Also, the progress
in mapping non-coding genes including microRNA and lincRNA genes on the dog genome
[57] may help to resolve this question in the future. The SRMA associated haplotype on chro-
mosome 3 is correlated with increased expression of the AP3B2 gene.
Interestingly, there is little overlap between the genes associated with SRMA and IMRD,
suggesting the involvement of largely distinct pathways in these phenotypes (Fig 8). While
most of the 11 genes are widely expressed, there is a certain emphasis on the predominant
brain, muscle and immune cells expression of SRMA genes AP3B2, PPP3CA, DDIT4L, DAPP1
and LAMTOR3 (S7 Fig), consistent with the involvement of the central nervous system and
muscles seen in this disease. Moreover, two genes, DDIT4L and PPP3CA, show relatively strong
association signals in human neuromuscular inflammatory conditions (S10 Table). Overall,
for nine dog genes out of eleven, there is either evidence or at least a trend of association with
various human autoimmune disorders, as can be viewed using the GRASP Search tool (http://
apps.nhlbi.nih.gov/Grasp/Search.aspx)[58].
Without wishing to be bound by a theory, we hypothesize that primary inflammation trig-
gered by as yet unknown environmental factors in SRMA-susceptible dogs is then maintained
by the over-activated B cells producing high titers of IgA, often detected in the serum and cere-
brospinal fluid (CSF) of SRMA patients [14, 56]. The enhanced function of DAPP1, PPP3CA
and LAMTOR3 acting downstream of the B cell receptor via MAPK signaling pathway may be
responsible for the altered B cell reactions. Moreover, the arteritis of the blood vessels may lead
to ischemia in CNS or myocardial infarction through decreased nutrient and oxygen supply by
damaged arteries and may further induce an already genetically modulated DDIT4L in neurons
Fig 8. Venn diagram showing overlaps between clinicopathologic features and associated genes.
*Muscle pain and fever occur in both ANA-positive groups, but were slightly more frequent in ANAS dogs in
the study cohort. ANAS showed an earlier onset of disease than ANAH (2 versus 3 years), while SRMA
affected dogs at even a younger age (4–19 months).
doi:10.1371/journal.pgen.1005248.g008
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or cardiac myocytes, which in turn inhibit mTOR signaling and activate autophagy (genes
LAMTOR3 and AP3B2 code for adaptor proteins in the lysosome-endosome system) and lead
to apoptosis or necrosis [59]. It is tempting to speculate here that the enhanced levels of brain-
specific expression of the SRMA-associated genes could be responsible also for hyperesthesia,
an extreme pain sensitivity condition mainly exhibited by cervical, neck and spinal pain, and
always seen in SRMA but not IMRD dogs [14].
Of note, out of four genes associated with ANAS IMRD only AP3B2, the gene also shared
with SRMA, shows the highest expression levels in the brain. In contrast, the ANAH genes
showed a more diverse pattern of expression with the highest levels in the following tissues:
blood (BANK1 and VRK1), skin and kidney (WFDC3), muscle and kidney (HOMER2), heart,
kidney and liver (PTPN3), muscle/heart, liver and kidney (WHAMM).
Many cellular pathways are interconnected and therefore it is difficult to predict the exact
biological effect, especially when several genes are altered, so the signaling output of each af-
fected gene in all three phenotypes, ANAH, ANAS and SRMA, will depend on a particular tis-
sue and cell context, the precise timing of expression and responsiveness to environmental
inducers. Thus, for instance, the highest shift in expression levels associated with SRMA was a
2.5-fold up-regulation observed for the DDIT4L gene (Fig 4H), DNA-damage-inducible tran-
script 4-like, known to be induced by a variety of stress factors, including hypoxia [60]. Al-
though the precise role of the encoded protein remains largely unknown, the function of
DDIT4L in autoimmunity may be related to the negative regulation of mTOR [61]. While the
inhibition of mTOR promotes generation of CD8+ memory T cells [62], at the same time it in-
duces cell death by necrosis in the culture of U-937 monocytes [63], which may trigger an
auto-inflammatory response.
In addition to the complexity of phenotypes relating to the different genes and genetic vari-
ants, the genomic architecture of almost all loci show a considerable complexity with SNPs
showing long-range effects on gene regulation either alone or in conjunction with other SNPs.
For example, the chromosome 3 top SNP (3:57,432,981) is a part of two different haplotypes
present in different sub-phenotypes. On chromosome 32, a haplotype associated with ANAS
exerts a distant effect on a gene located in the other part of the locus, while SNPs located inter-
nally in the region affect four other genes in SRMA. It remains to be shown whether this type
of complex regulatory structure will be a common finding in both canine and human disease,
or an unusual event found here due to the potentially strong natural selection applied when
only a handful of NSDTR dogs survived a canine distemper outbreak in the early 1900s [64] re-
mains to be seen.
In conclusion, we identified functional changes in eleven genes associated with different
sub-phenotypes of canine IMRD resembling human SLE, and with SRMA which share clinical
signs with a group of human vasulitides including Kawasaki disease, Henoch-Schönlein purpu-
ra and Behçet’s disease. Based on the gene functions and pattern of expression, we hypothesize
how different genetic factors, sometimes located in the same genomic region, may lead to di-
verse clinical manifestations. The common genes and pathways may account for overlapping
manifestations, whereas alterations in the functions of certain tissue-specific or even ubiquitous
genes may be linked to specific clinical signs. The strikingly complex pattern of genomic regu-
lation suggests that one should keep an open mind to multiple variants causing disease when
studying GWAS regions both in canine and human diseases. The utility of dog breeds in identi-
fication of disease genes underlying human complex diseases is demonstrated by the identifica-
tion of a well-known human SLE gene, BANK1, and several novel genes. The novel genes
warrant further study both in canine and human autoimmune disease.
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Materials and Methods
Ethics statement
This study was performed in strict accordance with the guidelines of the EU directive 2010/63
on the protection of animals used for scientific purposes. The protocols were approved by the
regional Ethical board for experimental animals in Uppsala, Sweden (Dnr C103/10 and C417/
12), and Animal Ethical Committee of County Administrative Board of Southern Finland
(ESAVI/6054/04.10.03/2012).
Study population and diagnostic procedures
250 Nova Scotia duck tolling retrievers (NSDTRs) were included in this study, 52 of them clas-
sified as ANA-positive IMRD cases, 66 as SRMA cases and 132 as healthy controls. All dogs in-
cluded were privately owned and samples were collected during 2002–2013. The dog pedigrees
were verified to exclude closely related animals (littermates) from the analysis. Individual dog
owners had consulted different veterinary clinics in Sweden and Finland. The inclusion criteria
for IMRD ANA-positive dogs were musculoskeletal signs indicating a systemic rheumatic dis-
order, including stiffness mainly after rest, and pain from several joints of extremities. These
signs had to be apparent for at least 14 days and were the main reason for the dog owner to
visit the veterinary clinic. The examining veterinary physician suspected no other diseases in
their diagnosis. All IMRD dogs should also display a positive IIF ANA test. Healthy controls
were above seven years of age with no history of autoimmune disease. All study dogs were veri-
fied for relatedness and those related were excluded from the analysis.
ANA tests were analyzed with indirect immunofluorescence at the University Animal Hos-
pital, Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden using monolayers of
HEp-2 cells fixed on glass slides (Immuno Concepts). The glass slides were examined by fluo-
rescence microscopy and considered positive at a titer of1:100. The visible nuclear fluores-
cence patterns could be divided into two groups; homogeneous (ANAH) or speckled (ANAS)
patterns as previously described[8].
DNA purification, PCR amplification of DLA regions and sequence
analysis
Genomic DNA was purified from 200 μl of blood using Qiagen QIAamp DNA Blood Mini Kit
(Qiagen) according to the manufacturer’s protocol.
DLA-DRB1,-DQA1 and DQB1 exon 2 were amplified by PCR as previously described[25].
DNA sequencing was performed using capillary electrophoresis on an Applied Biosys-
tems 3730xl. BigDye Terminator v3.1 (Applied Biosystems) Sequencing of the purified PCR
products was made in one direction, reverse for DLA-DRB1 and-DQA1 and forward for
DLA-DQB1. Analysis of the nucleotide sequence was performed using MatchTools and
MatchTools Navigator (Applied Biosystems) [25].
Statistical analysis
Statistical analyses were performed using VassarStats (http://vassarstats.net/odds2x2.html).
Odds ratios and p-values for each allele, haplotype and genotype were calculated using a 2x2
contingency table. The total number of cases and controls carrying a specific allele or genotype
was compared with the cases and controls not carrying it. The same comparison was made for
alleles as well as genotypes for the ANA-positive cases with homogeneous or speckled pattern
and the controls. The total numbers of homozygous dogs was also compared in cases
and controls.
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Next generation re-sequencing
To identify candidate variants, the five regions previously found associated with IMRD [27],
spanning approximately 5Mb, were re-sequenced in nine NSDTR individuals (four ANA cases,
two SRMA cases and three controls) using 385K custom designed capture arrays from Roche
NimbleGen and 400–600 X coverage Illumina sequencing. The sequencing data was aligned
with BWA (http://bio-bwa.sourceforge.net/) [65] and analyzed using SAMtools (http://
samtools.sourceforge.net/) [66], BEDTools (http://code.google.com/p/bedtools/) [67], SEQs-
coring [33] (http://www.seqscoring.org/) and other in-house tools to discover variants (SNPs,
indels and structural changes) in the genomic sequence between IMRD, SRMA and healthy
control dogs. A total of 13,084 potential SNPs were detected and of these, 426 SNPs were locat-
ed within or close (±5 bp) to a conserved element [39, 68]. 2780 possible InDels were detected,
among those, 88 occurred within or close to a conserved element (±5 bp). To identify structural
variations, such as larger insertions, CNV or deletions, SEQscoring was used to calculate cover-
age differences between cases and controls. We did not identify any structural variants that dif-
fered between cases and controls. Sequencing data was deposited in European Nucleotide
Archive (ENA) (Study accession: PRJEB6494, available at: http://www.ebi.ac.uk/ena/data/view/
PRJEB6494).
SNP selection for genotyping and association analysis
308 SNPs for five loci (chromosome 3, 8, 11, 24 and 32) were chosen from the re-sequencing
data. SNPs were chosen based on the following criteria: difference in allele frequency in cases
compared to controls, positioned in either protein coding regions, 5’UTR or 3’UTR and locat-
ed within non-coding conserved elements. Conserved elements were identified using compara-
tive sequence analysis based on the analysis of 29 mammals using SiPhy [39, 68]. These SNPs
were genotyped by GoldenGate Genotyping Assay. PLINK [69] (http://pngu.mgh.harvard.edu/
purcell/plink/) was used to analyze the markers with a MAF>0.05 and a call rate>0.75. Total
genotyping rate was 97%.
RNA extraction and cDNA synthesis
Peripheral blood was drawn from 165 healthy NSDTR dogs directly in Tempus Blood RNA
tubes (Applied Biosystems) and kept on ice during transportation. For isolation of total RNA
from different dog tissues, fresh tissue samples from euthanized dogs were immediately im-
mersed in the TRIZOL solution (Invitrogen) and RNA and DNA were purified according to
the manufacture’s protocol. Total RNA from blood was purified using the Tempus Spin RNA
Isolation Reagent kit (Applied Biosystems) according to the manufacturer’s instructions, and
the quantity and the quality of RNA was assessed by NanoDrop ND-1000 spectrophotometer
(Thermo Scientific). In parallel, genomic DNA was purified for each sample and genotyped
using pyrosequencing or direct Sanger sequencing with the primers shown in S11 Table.
cDNA synthesis was performed in 20 μL at 42°C for 80 min using 2 μg of total RNA, 5 μM
oligo-dT primer, MuLV transcriptase, RNase inhibitor in the buffer supplemented with 5 mM
MgCl2 and 1 mM dNTPs. All reagents were purchased from Applied Biosystems. The reaction
was terminated by heating for 5 min at 95°C and diluted to 25 ng/μl.
Quantitative RT-PCR
Gene expression was measured by quantitative real-time PCR on 7900HT Sequence Detector
(Applied Biosystems) with SDS 2.3 software using SYBR Green for signal detection. Gene-spe-
cific primers and annealing temperatures are shown in S12 Table in accordance with the
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guidelines for the minimum information for publication of quantitative real-time PCR experi-
ments (MIQE) [70]. The regions for primers’ design were selected to target all known tran-
scripts for a particular gene and thus allow to measure the total gene expression. In order to
avoid amplification from genomic DNA, primers were located to cover either several exons
separated by long introns or exon/exon junctions and further verified by BLAST search. The
PCR conditions were optimized for each primer set prior to qPCR, and the specificity of ampli-
fication was verified by the post-PCR analysis of melting curves and agarose gel analysis. Initial
denaturation at 95°C for 5 min was followed by 45 cycles (95°C for 15s, annealing at primer-
specific Tm for 15s and 72°C for 25s). PCR buffer (Invitrogen) was supplemented with 1.5 mM
MgCl2, 200 μM of each dNTPs, 0.2 μM of each primer, SYBRGreen (Molecular Probes), 15 ng
of cDNA and 0.5 U of Platinum Taq polymerase (Invitrogen). The reaction was carried out in
20 μL on a MicroAmp Optical 384-well reaction plate (Applied Biosytems). Expression levels
were normalized to the reference gene TBP using the comparative 2-ΔCt-method [71]. All ex-
periments were run in triplicate. Correlation of gene expression with genotypes and haplotypes
was performed using one-way ANOVA tests in PRISM 6 (GraphPad Software).
Luciferase reporter assay
The dog 550 bp genomic fragment containing SNP chr8:68,708,503 was amplified by PCR and
cloned in front of the minimal promoter in the pGL4.26 reporter vector (Promega). After se-
quence validation, the plasmids were purified with EndoFree Plasmid Maxi Kit (Qiagen). The
transfection of K562 cells was performed in the 24-well plates as follows: 7x105 cells/well were
seeded 24 hours before transfection in the RPMI-1640 medium supplemented with L-gluta-
mine and 10% of heat-inactivated bovine serum. 750 ng of the reporter plasmid and 50 ng of
the pRL-TK (Promega) normalization vector were transfected into each well by Lipofectamine
2000 (Invitrogen) according to the manufacture’s protocol. Twenty-four hours after transfec-
tion, cells were additionally stimulated with 20 ng/ml of PMA for 10 hours, then harvested and
assayed for the Firefly and Renilla luciferase activities with the Dual-Luciferase Reporter Assay
System (Promega). The experiment was repeated three times with four technical replicates for
each plasmid.
Supporting Information
S1 Fig. The comparative expression levels of genes from chromosome 32 locus. The gene ex-
pression was measured in the total RNA purified from canine blood and normalized to the lev-
els of the TBP gene.
(PDF)
S2 Fig. Tissue-specific expression of FSD2 in dogs analyzed by RT-PCR in total RNA puri-
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